Latest Proacta Incorporated Stories
SAN DIEGO, Aug 29, 2012 /PRNewswire/ -- Proacta Incorporated announced today that the US Food and Drug Administration has allowed its Investigational New Drug (IND) Application for PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer. The IND allowance permits Proacta to initiate human clinical trials of this novel, first in class treatment. Initially, development will focus on patients with non-small cell lung cancer who have developed...
SAN DIEGO, Aug. 3, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo: 2267) today announced the expansion of their Collaborative Research, Development and Commercialization Agreement to also include Proacta's PR610 compound, a hypoxia-activated pro-drug for the treatment of cancer. Based on compelling pre-clinical data on PR610, the parties agreed to expand their existing collaboration to include PR610. The initial agreement, signed in February 2011, for...
SAN DIEGO, Feb. 22, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo: 2267) today announced the execution of a definitive agreement relating to the collaborative research, development and commercialization of Proacta's PR509, a hypoxia-activated pro-drug for the treatment of cancer. (Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-a ) (Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-b ) "We have worked diligently to arrive at this...
